Subscribe
Core coverageSRRK

Company profile / SRRK

Scholar Rock

Clinaptis stanceCautious
ConvictionMedium
Ticker
SRRK
Exchange
NASDAQ
Coverage
Standard profile
Updated
Sep 11, 2026
Neuromuscular Disease / Myostatin Biology

Commercial-stage biopharmaceutical company developing selective myostatin inhibitors. ISEMBYLD (apitegromab) is now FDA-approved for spinal muscular atrophy, while Scholar Rock is extending the mechanism into FSHD and obesity through apitegromab and next-generation SRK-439.

01 / Clinaptis view

The current read

ISEMBYLD establishes myostatin inhibition as a clinically relevant mechanism in SMA, where patients already have substantial functional muscle deficit. We are considerably less convinced that this translates into a broad obesity opportunity.

  1. Apitegromab clearly preserves lean mass during GLP-1-induced weight loss, but EMBRAZE has not established that preserved tissue produces meaningful functional benefit, and the drug does not add meaningful fat or total weight loss. Regeneron’s COURAGE data strengthen the underlying muscle-preservation biology and suggest the effect may be more relevant in patients starting with low lean mass, but they do not yet close the mass-to-function gap.
  2. Our base case therefore treats obesity as a narrower sarcopenic/frailty opportunity until prospective data demonstrate that preserving muscle improves something patients, physicians or payers value beyond body composition.
02 / Consensus gap

Where the market may differ

The market may extrapolate a validated SMA mechanism and reproducible lean-mass preservation into a much larger obesity franchise. We think that extrapolation runs ahead of the evidence.

  1. The key distinction is not whether selective myostatin inhibition preserves muscle—it does—but whether muscle preservation alone has sufficient clinical and commercial utility in obesity. The most informative next data are functional outcomes in an enriched population with baseline muscle deficit, rather than another demonstration of improved DXA body composition.
Coverage state
Standard profile
What the review turns on
Key variable

Function before mass.

Next catalyst

SRK-439 · Phase 1 healthy-volunteer topline · Late 2026

03 / Pipeline

Key programs

2 assets · 4 programs

AssetIndicationStageNext event
Apitegromab
Spinal muscular atrophy
Approved
ISEMBYLD launch metrics · 4Q26 onwardCommercial uptake and execution remain important for SMA valuation
Spinal muscular atrophy in infants and toddlers
Phase 2
Ongoing OPAL enrollment and dosing
Facioscapulohumeral muscular dystrophy
Phase 2
FORGE Phase 2 · later readoutThe 52-week study began dosing around Sep 2026
SRK-439
Obesity / muscle preservation
Phase 1
Phase 1 healthy-volunteer topline · Late 2026PK/PD, potency, SC feasibility and target engagement; not yet a test of obesity utility
04 / Connected research

Published on SRRK

View full archive
  1. 01

    Lean Mass: Selectivity Is the Trap

    Selectivity makes apitegromab's lean-mass result (1.9 kg preserved vs. placebo) the cleanest in obesity — and the why exactly why it hasn't proven mass becomes function.

    Read